UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of
earliest event reported): August 18, 2023
TRADEUP ACQUISITION CORP.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-40608 |
|
86-1314502 |
(State or other jurisdiction |
|
(Commission File Number) |
|
(IRS Employer |
of incorporation) |
|
|
|
Identification Number) |
437 Madison Avenue, 27th Floor
New York, New York |
|
10022 |
(Address of principal executive offices) |
|
(Zip Code) |
(732) 910-9692
(Registrant’s telephone number, including
area code)
(Former name or former address, if changed since
last report.)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☒ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act.
Title of each class |
|
Trading Symbol |
|
Name of each exchange on which registered |
Units, each consisting of one share of Common Stock and one-half of one Warrant |
|
UPTDU |
|
The Nasdaq Stock Market LLC |
|
|
|
|
|
Common Stock, par value $0.0001 per share |
|
UPTD |
|
The Nasdaq Stock Market LLC |
|
|
|
|
|
Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 |
|
UPTDW |
|
The Nasdaq Stock Market LLC |
Indicate by check mark
whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or
Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Item 1.01 Entry
into a Material Definitive Agreement.
The
disclosure included under Item 2.03 is incorporated by reference.
Item
2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance
Sheet Arrangement of a Registrant
As
provided in an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise
modified from time to time, the “Merger Agreement”)
dated September 30, 2022 by and among TradeUP Acquisition Corp. (the “Company”),
Estrella Biopharma, Inc., a Delaware corporation (“Estrella”) and Tradeup
Merger Sub Inc., a Delaware corporation and wholly-owned subsidiary of UPTD (“Merger Sub”),
Estrella has agreed to, upon request by the sponsors of the Company, deposit the agreed reasonable amount to the Company’s trust
in order to effectuate extension of the Company’s deadline to consummate a business combination. Pursuant to the Merger Agreement,
Estrella has deposited a monthly extension payment of $37,432.70 to the trust account of the Company to extend the deadline for the Company
to complete the business combination contemplated therein by September 19, 2023. Such deposit is evidenced by an unsecured promissory
note in the principal amount of $37,432.70 issued by the Company to Estrella (the “Extension Note”).
The
Extension Note bears no interest and is payable in full upon the consummation of the Company’s business combination (the “Business
Combination”) (such date, the “Maturity Date”). The following shall constitute an event of default: (i) a failure to
pay the principal within five business days of the Maturity Date; (ii) the commencement of a voluntary or involuntary bankruptcy action,
(iii) the breach of the Company’s obligations thereunder; (iv) any cross defaults; (v) an enforcement proceedings against the Company;
and (vi) any unlawfulness and invalidity in connection with the performance of the obligations thereunder, in which case the Extension
Note may be accelerated.
Estrella
has the right, but not the obligation, to convert the Extension Note, in whole or in part, respectively, into private shares of the common
stock (the “Conversion Shares”) of the Company, as described in the prospectus of the Company (File Number 333-253322), by
providing the Company with written notice of the intention to convert at least two business days prior to the closing of the Business
Combination. The number of Conversion Shares to be received by Estrella in connection with such conversion shall be an amount determined
by dividing (x) the sum of the outstanding principal amount payable to Estrella by (y) $10.00, respectively. Notwithstanding the foregoing,
the Company shall have the obligation to pay to Estrella the funds amounting to the principal amount of the Extension Note if the proposed
business combination is terminated pursuant to the Merger Agreement. The Company shall refund the principal amount of the Extension Note
to Estrella fully within 5 business days of such termination.
The
issuance of the Extension Note was made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act
of 1933, as amended.
The
copy of the Extension Note is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. The
disclosures set forth in this Item 2.03 are intended to be summaries only and are qualified in their entirety by reference to the Extension
Note.
Item 3.02 Unregistered
Sales of Equity Securities.
The
information disclosed under Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.02 to
the extent required herein. The Conversion Shares, if any, (1) may not, subject to certain limited exceptions, be transferable or salable
by Estrella until 30 days after the completion of the Company’s initial Business Combination and (2) are entitled to registration
rights.
Item 8.01. Other Events.
The Company issued the press
release filed herewith on August 18, 2023, announcing the issuance of the Extension Note. The material attached as Exhibit 99.1 is incorporated
by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. The following exhibits are filed with this Form 8-K:
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
TradeUP Acquisition Corp. |
|
|
|
By: |
/s/ Weiguang Yang |
|
Name: |
Weiguang Yang |
|
Title: |
Co-Chief Executive Officer |
Date: August 18,
2023
3
Exhibit 10.1
THIS PROMISSORY NOTE (“NOTE”) HAS
NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT
ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN
OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.
PROMISSORY NOTE
Principal Amount: US$37,432.70
Dated: August 18, 2023
New York, New York
FOR VALUE RECEIVED, TradeUP Acquisition
Corp. (the “Maker” or the “Company”) promises to pay to the order of Estrella Biopharma, Inc., a
Delaware corporation, or its registered assignees or successors in interest (the “Payee”), the principal sum of
Thirty-Seven Thousand Four Hundred Thirty-Two and Seventy Cents (US$37,432.70), on the terms and conditions described below. All payments
on this Note shall be made by wire transfer of immediately available funds to such account as the Payee may from time to time designate
by written notice in accordance with the provisions of this note (the “Note”). The Note is issued pursuant to an Agreement
and Plan of Merger (the “Merger Agreement”), dated September 30, 2022, by and among the Maker, TradeUP Merger Sub Inc.,
a wholly owned-subsidiary of Maker and the Payee.
1. | Principal. The principal balance of this Note shall be payable by the Maker to the Payee upon the
date on which the Maker consummates a business combination with the Payee (the “Merger”) (such date, the “Maturity
Date”). The principal balance may be prepaid at any time prior to the Maturity Date without penalty. Under no circumstances
shall any individual, including but not limited to any officer, director, employee or stockholder of the Maker, be obligated personally
for any obligations or liabilities of the Maker hereunder. |
2. | Conversion Rights. The Payee has the right, but not the obligation, to convert this Note, in whole
or in part, into private shares of the common stock (the “Shares”) of the Maker, as described in the Prospectus of
the Maker (File Number 333-253322) (the “Prospectus”), by providing the Maker with written notice of its intention
to convert this Note at least two business days prior to the closing of the Merger. The number of Shares to be received by the Payee in
connection with such conversion shall be an amount determined by dividing (x) the sum of the outstanding principal amount payable to such
Payee by (y) $10.00. |
| (a) | Fractional Shares. No fractional Shares will be issued
upon conversion of this Note. In lieu of any fractional Shares to which Payee would otherwise be entitled, the Maker will pay to Payee
in cash the amount of the unconverted principal balance of this Note that would otherwise be converted into such fractional Share. |
| (b) | Effect of Conversion. If the Maker timely receives
notice of the Payee’s intention to convert this Note at least two business days prior to the closing of the Merger, this Note shall
be deemed to be converted on such closing date. At its expense, the Maker will, upon receipt of such conversion notice, as soon as practicable
after consummation of the Merger, issue and deliver to Payee, at Payee’s address as requested by Payee in its conversion notice,
a certificate or certificates for the number of Shares to which Payee is entitled upon such conversion (bearing such legends as are customary
pursuant to applicable state and federal securities laws), including a check payable to Payee for any cash amounts payable as a result
of any fractional Shares as described herein. |
3. | Mandatory Repayment. Notwithstanding the foregoing, the Maker shall have the obligation to pay
to the Payee the funds amounting to the principal amount of this Note if the Merger is terminated pursuant to the Merger Agreement. The
Maker shall refund the principal amount of this Note to the Payee fully within 5 business days of such termination. |
4. | Interest. This Note does not carry any interest on the unpaid principal balance of this Note, provided,
that, any overdue amounts shall accrue default interest at a rate per annum equal to the interest rate which is the prevailing short term
United States Treasury Bill rate, from the date on which such payment is due until the day on which all sums due are received by the Payee. |
5. | Application of Payments. All payments shall be applied first to payment in full of any costs incurred
in the collection of any sum due under this Note, including but not limited to reasonable attorney’s and auditor’s fees and
expenses, then to the payment in full of any late charges, and finally to the reduction of the unpaid principal balance of this Note. |
6. | Events of Default. The following shall constitute an event of default (each, an “Event
of Default”): |
| (a) | Failure to Make Required Payments. Failure by the
Maker to pay the principal amount due pursuant to this Note more than 5 business days of the Maturity Date. |
| (b) | Voluntary Bankruptcy, etc. The commencement by the
Maker of a voluntary case under any applicable bankruptcy, insolvency, reorganization, rehabilitation or other similar law, or the consent
by it to the appointment of or taking possession by a receiver, liquidator, assignee, trustee, custodian, sequestrator (or other similar
official) of the Maker or for any substantial part of its property, or the making by it of any assignment for the benefit of creditors,
or the failure of the Maker generally to pay its debts as such debts become due, or the taking of corporate action by the Maker in furtherance
of any of the foregoing. |
| (c) | Involuntary Bankruptcy, etc. The entry of a decree
or order for relief by a court having jurisdiction in the premises in respect of the Maker in an involuntary case under any applicable
bankruptcy, insolvency or other similar law, or appointing a receiver, liquidator, assignee, custodian, trustee, sequestrator (or similar
official) of the Maker or for any substantial part of its property, or ordering the winding-up or liquidation of its affairs, and the
continuance of any such decree or order unstayed and in effect for a period of 60 consecutive days. |
| (d) | Breach of Other Obligations. The Maker fails to perform
or comply with any one or more of its obligations under this Note. |
| (e) | Cross Default. Any present or future indebtedness
of the Maker in respect of moneys borrowed or raised becomes (or becomes capable of being declared) due and payable prior to its stated
maturity by reason of any event of default, or any such indebtedness is not paid when due or, as the case may be, within any applicable
grace period. |
| (f) | Enforcement Proceedings. A distress, attachment, execution
or other legal process is levied or enforced on or against any assets of the Maker which is not discharged or stayed within 30 days. |
| (g) | Unlawfulness and Invalidity. It is or becomes unlawful
for the Maker to perform any of its obligations under this Note, or any obligations of the Maker under this Note are not or cease to
be legal, valid, binding or enforceable. |
| (a) | Upon the occurrence of an Event of Default specified in Section
5(a) and 5(d) hereof, the Payee may, by written notice to the Maker, declare this Note to be due immediately and payable, whereupon the
unpaid principal amount of this Note, and all other amounts payable hereunder, shall become immediately due and payable without presentment,
demand, protest or other notice of any kind, all of which are hereby expressly waived, notwithstanding anything contained herein or in
the documents evidencing the same to the contrary. |
| (b) | Upon the occurrence of an Event of Default specified in Sections
5(b), 5(c), 5(e), 5(f) and 5(g) hereof, the unpaid principal balance of this Note, and all other sums payable with regard to this Note
hereunder, shall automatically and immediately become due and payable, in all cases without any action on the part of the Payee. |
8. | Taxes. The Maker will pay all amounts due hereunder
free and clear of and without reduction for any taxes, levies, imposts, deductions, withholding or charges imposed or levied by any governmental
authority or any political subdivision or taxing authority thereof with respect thereto (“Taxes”). The Maker will
pay on behalf of the Payee all such Taxes so imposed or levied and any additional amounts as may be necessary so that the net payment
of principal and any interest on this Note received by the Payee after payment of all such Taxes shall be not less than the full amount
provided hereunder. |
9. | Waivers. The Maker and all endorsers and guarantors
of, and sureties for, this Note waive presentment for payment, demand, notice of dishonor, protest, and notice of protest with regard
to the Note, all errors, defects and imperfections in any proceedings instituted by the Payee under the terms of this Note, and all benefits
that might accrue to the Maker by virtue of any present or future laws exempting any property, real or personal, or any part of the proceeds
arising from any sale of any such property, from attachment, levy or sale under execution, or providing for any stay of execution, exemption
from civil process, or extension of time for payment; and the Maker agrees that any real estate that may be levied upon pursuant to a
judgment obtained by virtue hereof or any writ of execution issued hereon, may be sold upon any such writ in whole or in part in any
order desired by the Payee. |
10. | Unconditional Liability. The Maker hereby waives all
notices in connection with the delivery, acceptance, performance, default, or enforcement of the payment of this Note, and agrees that
its liability shall be unconditional, without regard to the liability of any other party, and shall not be affected in any manner by
any indulgence, extension of time, renewal, waiver or modification granted or consented to by the Payee, and consents to any and all
extensions of time, renewals, waivers, or modifications that may be granted by the Payee with respect to the payment or other provisions
of this Note, and agrees that additional makers, endorsers, guarantors, or sureties may become parties hereto without notice to the Maker
or affecting the Maker’s liability hereunder. For the purpose of this Note, “business day” shall mean a day (other
than a Saturday, Sunday or public holiday) on which banks are open in China and New York for general banking business. |
11. | Notices. All notices, statements or other documents
which are required or contemplated by this Note shall be made in writing and delivered: (i) personally or sent by first class registered
or certified mail, overnight courier service to the address most recently provided in writing to such party or such other address as
may be designated in writing by such party, (ii) by fax to the number most recently provided to such party or such other fax number as
may be designated in writing by such party, or (iii) by email, to the email address most recently provided to such party or such other
email address as may be designated in writing by such party. Any notice or other communication so transmitted shall be deemed to have
been given on (a) the day of delivery, if delivered personally, (b) only if the receipt is acknowledged, the day after such receipt,
if sent by fax or email, (c) the business day after delivery to an overnight courier service, if sent by an overnight courier service,
or (d) 5 days after mailing if sent by first class registered or certified mail. |
12. | Construction. This Note shall be construed and enforced
in accordance with the laws of New York, without regard to conflict of law provisions thereof. |
13. | Severability. Any provision contained in this Note
which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition
or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction
shall not invalidate or render unenforceable such provision in any other jurisdiction. The Payee hereby waives any and all right, title,
interest or claim of any kind (“Claim”) in or to any amounts contained in the trust account deriving from the proceeds
of the IPO conducted by the Maker and the proceeds of the sale of securities in a private placement (if any) prior to the effectiveness
of the IPO, as described in greater detail in the Prospectus filed with the Securities and Exchange Commission in connection with the
IPO (the “Trust Account Funds”), and hereby agrees not to seek recourse, reimbursement, payment or satisfaction for
any Claim from the Trust Account Funds or any distribution therefrom for any reason whatsoever. If Maker does not consummate the Merger,
this Note shall be repaid only from amounts other than Trust Account Funds, if any. |
14. | Amendment; Waiver. Any amendment hereto or waiver
of any provision hereof may be made with, and only with, the written consent of the Maker and the Payee. |
15. | Assignment. This Note shall be binding upon the Maker
and its successors and assigns and is for the benefit of the Payee and its successors and assigns, except that the Maker may not assign
or otherwise transfer its rights or obligations under this Note. The Payee may at any time without the consent of or notice to the Maker
assign to one or more entities all or a portion of its rights under this Note. |
[signature page follows]
The Parties, intending to be legally bound hereby,
have caused this Note to be duly executed by the undersigned as of the day and year first above written.
MAKER:
TradeUP Acquisition Corp.
By: |
/s/ Weiguang Yang |
|
Name: |
Weiguang Yang |
|
Title: |
Co-CEO and Director |
|
PAYEE:
Estrella Biopharma, Inc.
By: |
/s/ Peter Xu |
|
Name: |
Peter Xu |
|
Title: |
Chief Financial Officer |
|
[signature page to the promissory note]
5
Exhibit 99.1
TradeUP Acquisition Corp. Announces
Extension of the Deadline for an Initial Business
Combination
New York, August 18, 2023 /PRNewswire/ -- TradeUP
Acquisition Corp. (the “Company” or “TradeUP”) (NASDAQ: UPTD) today announced that, in order to extend the date
by which the Company must complete its initial business combination from August 19, 2023 to September 19, 2023, for each public share
that is not redeemed by the Company’s stockholders in connection with such extension (collectively, the “Remaining Shares”,
each, a “Remaining Share”), the Company has deposited into its trust account (the “Trust Account”) an aggregate
of $37,432.70 (the “Monthly Extension Fee”), representing $0.05 per Remaining Share of the Company.
The payment for such Monthly Extension Fee was
made by Estrella Biopharma, Inc., a Delaware corporation (“Estrella”), pursuant to the Agreement and Plan of Merger (the “Merger
Agreement”), entered by and among the Company, Tradeup Merger Sub Inc., a Delaware corporation and direct and wholly owned subsidiary
of UPTD (“Merger Sub”), and Estrella on September 30, 2022.
Pursuant to the Company’s current Charter,
the Company may extend on monthly basis from July 19, 2023 to July 14, 2024 or such an earlier date as may be determined by its board
to complete a business combination by depositing the Monthly Extension Fee for each month into the Trust Account.
About TradeUP
TradeUP Acquisition Corp. is a blank check company
formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business
combination with one or more businesses. TradeUP was incorporated under the laws of the State of Delaware on January 6, 2021.
About Estrella
Estrella Biopharma, Inc., a Delaware corporation,
is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS®️ T-cell therapies with the capacity
to address treatment challenges for patients with blood cancers and solid tumors. Estrella’s mission is to harness the evolutionary
power of the human immune system to transform the lives of patients fighting cancer.
Important Additional Information Regarding
the Transaction Will Be Filed With the SEC
TradeUP has filed with the SEC a registration
statement on Form S-4 (File No.: 333-267918) containing a preliminary proxy statement and a preliminary prospectus of TradeUP containing
information about the proposed business combination and the respective businesses of TradeUP and Estrella, which was declared effective
on July 11, 2023. TradeUP has mailed a definitive proxy statement/prospectus relating to the proposed business combination (the “Proxy
Statement/Prospectus”) to its stockholders and Estrella’s shareholders. This press release does not contain all the information
that should be considered concerning the proposed business combination and is not intended to form the basis of any investment decision
or any other decision in respect of the business combination. TradeUP’s stockholders and other interested persons are advised to
read, when available, the Proxy Statement/Prospectus and other documents filed in connection with the proposed business combination, as
these materials will contain important information about Estrella, TradeUP and the proposed business combination. The Proxy Statement/Prospectus
and other relevant materials for the proposed business combination have been mailed to stockholders of TradeUP as of a record date of
June 13, 2023. Such stockholders will also be able to obtain copies of the preliminary proxy statement/prospectus, the definitive proxy
statement/prospectus and other documents filed with the SEC, without charge, once available, at the SEC’s website at www.sec.gov,
or by directing a request to TradeUP Acquisition Corp., 437 Madison Avenue, 27th Floor, New York, New York 10022, and its telephone number
is (732) 910-9692, Attention: Jianwei Li, Co-Chief Executive Officer.
Forward-Looking Statements
This press release contains forward-looking statements
within the meaning of section 27A of the U.S. Securities Act of 1933, as amended (the “Securities Act”), and section 21E of
the U.S. Securities Exchange Act of 1934 (“Exchange Act”) that are based on beliefs and assumptions and on information currently
available to TradeUP and Estrella. In some cases, you can identify forward-looking statements by the following words: “may,”
“will,” “could,” “would,” “should,” “expect,” “intend,” “plan,”
“anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,”
“continue,” “ongoing,” “target,” “seek” or the negative or plural of these words, or other
similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these
words. Any statements that refer to expectations, projections or other characterizations of future events or circumstances, including
projections of market opportunity and market share, the capability of Estrella’s business plans including its plans to expand, the
sources and uses of cash from the proposed transaction, the anticipated enterprise value of the combined company following the consummation
of the proposed transaction, any benefits of Estrella’s partnerships, strategies or plans as they relate to the proposed transaction,
anticipated benefits of the proposed transaction and expectations related to the terms and timing of the proposed transaction are also
forward-looking statements. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity,
performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Although each
of TradeUP and Estrella believes that it has a reasonable basis for each forward-looking statement contained in this communication, each
of TradeUP and Estrella caution you that these statements are based on a combination of facts and factors currently known and projections
of the future, which are inherently uncertain. In addition, there are risks and uncertainties described in the Proxy Statement/Prospectus
relating to the proposed transaction and other documents filed by TradeUP or Estrella from time to time with the SEC. These filings may
identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those
contained in the forward-looking statements. Neither TradeUP nor Estrella can assure you that the forward-looking statements in this communication
will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including, among others,
the ability to complete the business combination due to the failure to obtain approval from TradeUP’s stockholders or satisfy other
closing conditions in the business combination agreement, the occurrence of any event that could give rise to the termination of the business
combination agreement, the ability to recognize the anticipated benefits of the business combination, the amount of redemption requests
made by TradeUP’s public stockholders, costs related to the transaction, the impact of the global COVID-19 pandemic, the risk that
the transaction disrupts current plans and operations as a result of the announcement and consummation of the transaction, the outcome
of any potential litigation, government or regulatory proceedings and other risks and uncertainties, including those to be included under
the heading “Risk Factors” in the Proxy Statement/Prospectus , the final prospectus
for TradeUP’s initial public offering filed with the SEC on June 19, 2021, its Annual
Report on Form 10-K and in its subsequent quarterly reports on Form 10-Q and other filings with the SEC. There may be additional
risks that neither TradeUP or Estrella presently know or that TradeUP and Estrella currently believe are immaterial that could also cause
actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking
statements, you should not regard these statements as a representation or warranty by TradeUP, Estrella, their respective directors, officers
or employees or any other person that TradeUP and Estrella will achieve their objectives and plans in any specified time frame, or at
all. The forward-looking statements in this press release represent the views of TradeUP and Estrella as of the date of this communication.
Subsequent events and developments may cause those views to change. However, while TradeUP and Estrella may update these forward-looking
statements in the future, there is no current intention to do so, except to the extent required by applicable law. You should, therefore,
not rely on these forward-looking statements as representing the views of TradeUP or Estrella as of any date subsequent to the date of
this communication.
TradeUP Acquisition (NASDAQ:UPTDU)
過去 株価チャート
から 9 2024 まで 10 2024
TradeUP Acquisition (NASDAQ:UPTDU)
過去 株価チャート
から 10 2023 まで 10 2024